David Domzalski - 30 Nov 2024 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Mutya Harsch, Attorney-in-Fact
Issuer symbol: VYNE
Transactions as of: 30 Nov 2024
Net transactions value: +$8,192
Form type: 4
Filing time: 03 Dec 2024, 16:15:06 UTC
Previous filing: 02 Oct 2024
Next filing: 02 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VYNE	Common Stock	Award	$8,192	+3,901	+0.79%	$2.10	500,597	30 Nov 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2024 and ending on November 30, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on June 3, 2024 (the first trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.

Content

These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2024 and ending on November 30, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on June 3, 2024 (the first trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.